EVM14 with or without Pembrolizumab for Solid Tumors
This study is testing a new cancer vaccine called EVM14, by itself and in combination with an existing immunotherapy drug called pembrolizumab. It aims to see how safe EVM14 is, how well people tolerate it, and if it shows any early signs of shrinking tumors in people with certain types of advanced, recurrent, or metastatic solid tumors. To join, you must have a confirmed solid tumor that cannot be removed by surgery, and your overall health status (ECOG PS) must be 0 or 1. The study is looking for 94 participants. We don't yet know if the study is actively recruiting.
- Study design
- This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It has two phases: Phase I and Phase IIa, and will involve up to 94 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- If you participate, your health will be monitored for side effects for up to 90 days after your last study treatment. For some participants, tumor progression will be tracked for up to 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
At a glance
Conditions
NCT07095868
Where you'd take part
This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Hunan Cancer Hospital
Changsha, Hunan, Chinastudy coordinator listed
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New Yorkstudy coordinator listed
Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, Chinastudy coordinator listed
Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, Chinastudy coordinator listed
Recruiting
The First Affiliated Hospital With Nanjing Medical University
Nanjing, Jiangsu, Chinastudy coordinator listed
Recruiting
MD Anderson Cancer Center
Houston, Texasno site contact published
Recruiting
NEXT Oncology
Fairfax, Virginiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase I and Phase IIa: Incidence and severity of adverse eventsFrom the the start of the first dose of study treatment to 90 days after the last study treatment or new anti-cancer treatments started, whichever occurs earlier.
- Phase I: Incidence of dose-limiting toxicities (DLT)Mono cohort: 28-day period from the first EVM14 monotherapy dose. Combo cohort: Days 1 to 21: 21-day period from the first dose of EVM14 in combination with pembrolizumab.
- Phase IIa tumor type 1: Progression-free survival (PFS)From the baseline to disease progression confirmed by radiological examination, the start of a new anti-cancer treatment, withdrawal of informed consent, lost to follow-up, death, or end of study, whichever occurs first. (Up to 3 years)
The time from date of randomization to the first documented disease progression per RECIST 1.1 evaluated by Investigators or death due to any cause, whichever occurs first.